Company*
(Country; Symbol)

Product

Description

Indication

Status (Date)


AUTOIMMUNE

Actelion Ltd.
(Switzerland;
SWX:ATLN)

Tracleer (FDA-
approved)

Bosentan; orally active endothelin receptor antagonist

Digital ulcerations
in scleroderma

Clinical results showed the primary endpoint, preventing new digital ulcers, was achieved (8/15)

Genentech Inc.
(NYSE:DNA) and
XOMA Ltd. (XOMA)

Raptiva (formerly Xanelim)

Efalizumab; humanized antibody

Psoriasis

Phase III data showed that most patients who complete one year of therapy maintain a 50% or greater improvement in their condition (8/2)

Ligand
Pharmaceuticals
Inc. (LGND)

Avinza

Morphine sulfate extended-release capsules

Osteoarthritis
pain

Avinza provided stable analgesia for one year without an increase in the use of rescue medicines (8/20)

CANCER

Allos Therapeutics
Inc.
(ALTH)

RSR13

Efaproxiral; a synthetic allosteric modifier of hemoglobin

Brain metastases

Company completed enrollment in a pivotal Phase III trial (8/6)

Allos Therapeutics
Inc.
(ALTH)

RSR13

Efaproxiral; a synthetic allosteric modifier of hemoglobin

Cervical cancer

Company initiated a Phase I/II trial (8/14)

Antisoma plc
(UK; LSE:ASM)

TheraFab

Member of the HMFG-1 family of antibody pro- ducts, which bind to the tumor antigen MUC1

Non-small-cell
lung cancer

Company completed recruitment in a Phase I trial (8/22)

Aton Pharma Inc.*

-

Suberoylanilide hydroxamic acid

Tumors

Phase I results were encouraging (8/19)

BioMedicines Inc.*

Biomed 101

Drug that binds to
the leukotriene B4
receptor

Metastatic renal cancer

Company completed enrollment in a Phase Ib trial (8/7)

Cell Pathways Inc.
(CLPA)

Aptosyn

Exisulind; first-
generation selective apoptotic antineoplastic drug

Lung cancer

Company said the National Cancer Institute is sponsoring two Phase II studies of Aptosyn in combination therapies; Phase I results showed the drug combination was well tolerated (8/27)

Cell Therapeutics
Inc.
(CTIC)

Xyotax

Polyglutamate
paclitaxel

Metastatic breast cancer

Company began a Phase II study (8/1)

Cell Therapeutics
Inc.
(CTIC)

Xyotax

Polyglutamate
paclitaxel

Recurrent ovarian cancer

Company began a Phase II study (8/14)

Cytokinetics Inc.*

-

Small-molecule
inhibitor of kinesin spindle protein

Cancer

Company began a Phase I trial (8/12)

Dendreon Corp.
(DNDN)

Provenge

Therapeutic vaccine

End-stage prostate cancer

Phase III data showed Provenge narrowly missed its primary endpoint, time to objective disease progression, but that it works well in men with a Gleason score of 7 or less (8/9)

Genentech Inc.
(NYSE:DNA), OSI Pharmaceuticals Inc. (OSIP) and F. Hoffmann-La Roche Ltd. (Switzerland)

Tarceva

Erlotinib HCl; small- molecule epidermal growth factor receptor inhibitor

Chemotherapy- naive Stage IIIB/ IV non-small-cell lung cancer

Companies completed patient enrollment in a Phase III trial (8/1)

ImmunoGen Inc.
(IMGN) and British Biotech plc (UK; BBIOY; LSE:BBG)

huN901-DM1/ BB-10901

Tumor-activated
prodrug

Small-cell lung cancer

Patient treatment is under way in the planned second Phase I study (8/8)

Large Scale Biology
Corp.
(LSBC)

-

Personalized therapeutic vaccines that use Nicotiana plants with viral vectors for the expression of relevant proteins

Non-Hodgkin's lymphoma

Company reported initial safety results from Phase I trials that were "promising" (8/6)

Maxim
Pharmaceuticals
Inc. (MAXM)

MX8899

Topical gel; histamine dihydrochloride

Oral mucositis related to chemotherapy and radiation therapy

Company began a clinical trial with up to 60 patients (8/19)

NeoPharm Inc.
(NEOL)

IL13-PE38

Tumor-targeting
product

Recurrent or progressive malignant glioma

Enrollment began in the first global six-site Phase I/II trial (8/16)

OraPharma Inc.
(OPHM)

OC-1012

Topical drug

Mucositis in bone marrow transplant patients undergoing chemotherapy

Company completed a Phase I trial and uncovered no safety issues with the compound (8/7)

Pharmacyclics Inc.
(PCYC)

Xcytrin

Motexafin
gadolinium

Non-small-cell lung cancer

Company planned to begin a Phase III trial with Xcytrin following a meeting with the FDA (8/22)

Seattle Genetics
Inc.
(SGEN)

SGN-15

cBR96-doxorubicin immunoconjugate; antibody drug conjugate product candidate

Advanced ovarian cancer

Company initiated a Phase II trial (8/20)

Tularik Inc.
(TLRK)

T67

A drug that binds irreversibly to beta-tubulin

Hepatocellular carcinoma

Company plans to begin a pivotal Phase III trial with 750 patients (8/27)

Vion Pharmaceuticals
Inc.
(VION)

VNP40101M

Drug candidate from the sulfonyl hydrazine prodrug family of anticancer agents

Leukemia

Company began a Phase I trial (8/8)

CARDIOVASCULAR

Actelion Ltd.
(Switzerland; SWX:ATLN)

Tracleer (FDA-
approved)

Bosentan; orally active endothelin receptor antagonist

Pulmonary arterial hypertension

Clinical results of Tracleer in com- bination with intravenous epoprostenol showed a greater improvement in total pulmonary vascular resistance, compared to those receiving epoprostenol alone (8/7)

Avant Immuno-
therapeutics Inc.
(AVAN)

CETi-1

Cholesterol management vaccine

Low levels of high-density lipoprotein cholesterol

Company completed enrollment in a Phase II study (8/1)

ConjuChem Inc.
(Canada; TSE:CJC)

DAC:TI

A locally acting thrombin inhibitor designed to prevent localized clotting

Blood clots

Company is discontinuing development in a Phase I trial, which showed the product was safe; efficacy trials would be too costly, the company said (8/9)

Dyax Corp.
(DYAX)

DX-88

A small protein that inhibits an enzyme in the blood called kallikrein

Cardiopulmonary bypass

Company initiated a Phase I/II trial to evaluate DX-88 in patients undergoing cardiopulmonary bypass (8/28)

Hollis-Eden
Pharmaceuticals
Inc. (HEPH)

HE2200

Immune-regulating hormone

Elevated cholesterol

Company will begin a Phase II trial (8/5)

InterMune Inc.
(ITMN)

Actimmune (FDA-
approved)

Interferon gamma-1b

Idiopathic pulmonary fibrosis

Phase III data showed Actimmune failed to meet its primary endpoint of progression-free survival, but did show a survival benefit (8/28)

Sangart Inc.*

Hemospan

An oxygen transport technology; a chemically modified hemoglobin solution prepared from outdated human blood

For red blood cell transfusions

Company reported no adverse events in a Phase I trial (8/2)

Viron Therapeutics
Inc.*
(Canada)

VT-111

Anti-inflammatory therapy

Cardiovascular disease

Company began a Phase I trial (8/19)

CENTRAL NERVOUS SYSTEM

Cellegy
Pharmaceuticals
Inc. (CLGY)

-

Topical nitroglycerin

Vulvodynia

Clinical results showed an improvement in pain was reported by 91.5% of the 34 patients; a common side effect was headache (8/21)

Cephalon Inc.
(CEPH) and H.
Lundbeck
A/S (Denmark)

CEP-1347

Orally active and cell- and blood-brain-barrier permeable small-molecule inhibitor of stress-activated protein kinase pathway

Parkinson's
disease

Companies initiated a North American Phase II/III trial (8/1)

ConjuChem Inc.
(Canada; TSE:CJC)

DAC:Opioid

Created with ConjuChem's Drug Affinity Complex technology, giving the drug a longer duration of activity in the body

Moderate to
severe pain

Company reported mixed results from three clinical trials, which showed the product to be safe, but it did not meet its primary endpoint (8/9)

DOV Pharmaceutical
Inc.
(DOVP)

Bicifadine

A chemically distinct molecule that enhances and prolongs the actions of norepinephrine and serotonin

Post-surgical
dental pain

Phase II results showed the agent was effective compared to placebo and at least equivalent to codeine (8/7)

Pozen Inc. (POZN)

MT 100

Formulation of two approved drugs, a fast- release metoclopramide and naproxen sodium

Migraine pain

Phase IIIb results showed MT 100 provided superior sustained pain relief and two-hour pain relief compared to placebo (8/22)

Transition
Therapeutics Inc.
(Canada; CDNX:TTH)

-

Interferon-enhancing therapy

Multiple sclerosis

Company began a Phase I trial (8/20)

DIABETES

Selective Genetics
Inc.*

Gene-Activated Matrix to
Selective
Genetics

Technology developed
at the University of Michigan and licensed

Chronic diabetic foot ulcers

Company began treating the first patient in a Phase I study (8/28)

INFECTION

Advanced Viral
Research Corp.
(ADVR)

Product R

A biopolymer chemistry that possesses novel immunomodulator activity; a peptide- nucleic acid

HIV/AIDS

Clinical results published in the July/August 2002 issue of HIV Clinical Trials showed a statistically significant increase in CD4- positive lymphocytes and weight gain in treated patients (8/20)

ProdiGene Inc.*

-

Oral corn vaccine, produced using its transgenic plant technology

Travelers'
diarrhea

Company began a Phase I trial (8/12)

Stressgen
Biotechnologies
Corp. (Canada; TSE:SSB)

HspE7

Immunotherapeutic to treat diseases caused by the human papillomavirus

Recurrent respiratory papillomatosis

Company completed enrollment in a Phase II trial (8/8)

The Immune
Response Corp.
(IMNR)

Remune

HIV-1 immunogen

HIV

Clinical results showed that Remune might give relief for HIV-infected patients from the adverse side effects of antiretroviral therapies (8/15)

MISCELLANEOUS

AVI BioPharma Inc.
(AVII)

AVI-4126

Neugene antisense
drug

Polycystic kidney disease

Company completed a Phase Ib trial of AVI-4126 (8/1)

CollaGenex
Pharmaceuticals
Inc. (CGPI)

Periostat
(FDA-
approved)

Doxycyline hyclate

Rosacea

Company began a Phase III trial and is enrolling 210 patients (8/13)

Corgentech Inc.*

E2F Decoy

An oligonucleotide or short strand of DNA; designed to block neointimal hyperplasia and redirect graft biology to strengthen the vessel wall

To prevent graft failure following coronary arterial bypass grafting surgery

Company started enrolling 2,500 patients in a Phase III trial (8/14)

Eyetech
Pharmaceuticals

Inc.*

Macugen

An aptamer designed to bind and neutralize vascular endothelial growth factor

Wet age-related macular degeneration

Eyetech completed enrollment in its two Phase III trials (8/7)

Genaera Corp.
(GENR)

Squalamine

Angiogenesis inhibitor that blocks a number of angiogenic growth factors, including vascular endothelial growth factor

Wet age-related macular degeneration

Company began a Phase I/II trial with 40 patients (8/21)

Immusol Inc.*

VitrenASE

A product expected to reduce the incidence of repeat retinal detachment in patients who undergo surgical repair

Proliferative vitreoretinopathy

Company began a Phase II trial (8/13)

Incara Pharmaceutical Corp. (INCR) agent

Deligoparin

Oligosaccharide
product that is a derivative of heparin, an anti-clotting

Ulcerative colitis

Company stopped a Phase II/III trial three months early due to limited financial resources (8/26)

Inspire
Pharmaceuticals
Inc. (ISPH)

INS37217

A P2Y(2) agonist; intranasal

Perennial allergic
rhinitis

Phase II data showed statistically significant improvement in treatment groups compared to placebo (8/13)

Metabolic
Pharmaceuticals
Ltd. (Australia; ASX:MBP)

AOD9604

Injection; human growth hormone

Obesity

Company completed its Phase IIa trial by single-dose oral administration (8/27)

Miravant Medical Technologies (MRVT)

SnET2

Tin ethyl etiopurpurin; photodynamic therapy

Wet age-related macular degeneration

Phase III data showed that subsets of patients demonstrated stabilized or improved visual acuity at two years, although SnET2 did not achieve the primary efficacy endpoint when all patients were included (8/27)

Neurochem Inc. (Canada; TSE:NRM)

Fibrillex

Anti-amyloid drug

Secondary amyloidosis continue (8/28)

The Data Safety Monitoring Board unanimously recommended the Phase II/III trial for Fibrillex

NexMed Inc.
(NEXM)

Alprox-TD

Cream treatment, which incorporates alprostadil, an off-patent vasodilator, with NexMed's NexACT platform technology

Erectile
dysfunction

Company closed enrollment of two Phase III studies (8/13)

QLT Inc. (Canada;
QLTI) and Novartis Ophthalmics (unit of Novartis AG; Switzerland)

Visudyne
(FDA-
approved)

Verteporfin therapy

Predominantly classic subfoveal choroidal neovascularization

Company completed enrollment in a Phase IIIb trial (8/27)

Texas Biotechnology
Corp.
(TXBI) and its subsidiary, Revotar Biopharmaceuticals AG (Germany)

Bimosiamose

Inhaled therapy; small-molecule selectin antagonist

Asthma

Companies initiated a Phase IIa trial (8/27)


Notes:

* Privately held.

Unless otherwise noted, the stock symbols listed for public companies are on the Nasdaq market.

ASX = Australian Stock Exchange; CDNX = Canadian Venture Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange